162 related articles for article (PubMed ID: 36509000)
21. HELOISE: Phase IIIb Randomized Multicenter Study Comparing Standard-of-Care and Higher-Dose Trastuzumab Regimens Combined With Chemotherapy as First-Line Therapy in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma.
Shah MA; Xu RH; Bang YJ; Hoff PM; Liu T; Herráez-Baranda LA; Xia F; Garg A; Shing M; Tabernero J
J Clin Oncol; 2017 Aug; 35(22):2558-2567. PubMed ID: 28574779
[TBL] [Abstract][Full Text] [Related]
22. A population-based study on treatment and outcomes in patients with gastric adenocarcinoma diagnosed with distant interval metastases.
Dijksterhuis WPM; Kroese TE; Verhoeven RHA; van Rossum PSN; Mook S; Haj Mohammad N; Hulshof MCCM; Gisbertz SS; Ruurda JP; van Oijen MGH; van Hillegersberg R; van Laarhoven HWM
Eur J Surg Oncol; 2022 Sep; 48(9):1964-1971. PubMed ID: 35314096
[TBL] [Abstract][Full Text] [Related]
23. [Prognostic factors of patients with unresectable liver metastasis from colorectal cancer after failed conversion chemotherapy].
He H; Shen W; Chen W; Liu H; Gong W; Fu J; Hu X; Cui L
Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Nov; 21(11):1261-1267. PubMed ID: 30506537
[TBL] [Abstract][Full Text] [Related]
24. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.
Janjigian YY; Shitara K; Moehler M; Garrido M; Salman P; Shen L; Wyrwicz L; Yamaguchi K; Skoczylas T; Campos Bragagnoli A; Liu T; Schenker M; Yanez P; Tehfe M; Kowalyszyn R; Karamouzis MV; Bruges R; Zander T; Pazo-Cid R; Hitre E; Feeney K; Cleary JM; Poulart V; Cullen D; Lei M; Xiao H; Kondo K; Li M; Ajani JA
Lancet; 2021 Jul; 398(10294):27-40. PubMed ID: 34102137
[TBL] [Abstract][Full Text] [Related]
25. The role of hepatectomy for synchronous liver metastases from pancreatic adenocarcinoma.
Andreou A; Knitter S; Klein F; Malinka T; Schmelzle M; Struecker B; Schmuck RB; Noltsch AR; Lee D; Pelzer U; Denecke T; Pratschke J; Bahra M
Surg Oncol; 2018 Dec; 27(4):688-694. PubMed ID: 30449494
[TBL] [Abstract][Full Text] [Related]
26. A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction.
Shah MA; Cho JY; Tan IB; Tebbutt NC; Yen CJ; Kang A; Shames DS; Bu L; Kang YK
Oncologist; 2016 Sep; 21(9):1085-90. PubMed ID: 27401892
[TBL] [Abstract][Full Text] [Related]
27. [Trastuzumab combined with chemotherapy in patients with HER2-positive chemo-refractory advanced gastric or gastro-esophageal junction adenocarcinoma].
Zhang X; Wu Y; Gong J; Lu Z; Zhou J; Wang X; Lu M; Li J; Cao Y; Li Y; Li J; Shen L
Zhonghua Zhong Liu Za Zhi; 2014 Mar; 36(3):223-7. PubMed ID: 24785285
[TBL] [Abstract][Full Text] [Related]
28. Association of Endocrine Therapy for HR+/ERBB2+ Metastatic Breast Cancer With Survival Outcomes.
Carausu M; Carton M; Diéras V; Petit T; Guiu S; Gonçalves A; Augereau P; Ferrero JM; Levy C; Ung M; Desmoulins I; Debled M; Bachelot T; Pistilli B; Frenel JS; Mailliez A; Chevrot M; Cabel L
JAMA Netw Open; 2022 Dec; 5(12):e2247154. PubMed ID: 36520434
[TBL] [Abstract][Full Text] [Related]
29. Prognostic Value of Site-Specific Metastases and Therapeutic Roles of Surgery and Chemotherapy for Patients With Metastatic Renal Pelvis Cancer: A SEER Based Study.
Chen WK; Wu ZG; Xiao YB; Wang QQ; Yu DD; Cai J; Zhou CF
Technol Cancer Res Treat; 2021; 20():15330338211004914. PubMed ID: 33929915
[TBL] [Abstract][Full Text] [Related]
30. Improved Overall Survival With Comprehensive Local Consolidative Therapy in Synchronous Oligometastatic Non-Small-Cell Lung Cancer.
Mitchell KG; Farooqi A; Ludmir EB; Corsini EM; Zhang J; Sepesi B; Vaporciyan AA; Swisher SG; Heymach JV; Zhang J; Gomez DR; Antonoff MB
Clin Lung Cancer; 2020 Jan; 21(1):37-46.e7. PubMed ID: 31447303
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of the prognostic value of the ESTRO EORTC classification of oligometastatic disease in patients treated with stereotactic body radiotherapy: A retrospective single center study.
Willmann J; Vlaskou Badra E; Adilovic S; Ahmadsei M; Christ SM; van Timmeren JE; Kroeze SGC; Mayinger M; Guckenberger M; Andratschke N
Radiother Oncol; 2022 Mar; 168():256-264. PubMed ID: 35101466
[TBL] [Abstract][Full Text] [Related]
32. Oncological outcomes of patients with oligometastatic oesophagogastric cancer.
Down B; Lakunina S; Maynard N; Markar SR; Gordon-Weeks A
Eur J Surg Oncol; 2024 Apr; 50(4):108231. PubMed ID: 38461569
[TBL] [Abstract][Full Text] [Related]
33. Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma: NEOHX phase II trial.
Rivera F; Izquierdo-Manuel M; García-Alfonso P; Martínez de Castro E; Gallego J; Limón ML; Alsina M; López L; Galán M; Falcó E; Manzano JL; González E; Muñoz-Unceta N; López C; Aranda E; Fernández E; Jorge M; Jiménez-Fonseca P
Eur J Cancer; 2021 Mar; 145():158-167. PubMed ID: 33485079
[TBL] [Abstract][Full Text] [Related]
34. Long-term outcomes in radically treated synchronous vs. metachronous oligometastatic non-small-cell lung cancer.
Fleckenstein J; Petroff A; Schäfers HJ; Wehler T; Schöpe J; Rübe C
BMC Cancer; 2016 Jun; 16():348. PubMed ID: 27255302
[TBL] [Abstract][Full Text] [Related]
35. Resection of hepatic and pulmonary metastasis from metastatic esophageal and gastric cancer: a nationwide study.
Seesing MFJ; van der Veen A; Brenkman HJF; Stockmann HBAC; Nieuwenhuijzen GAP; Rosman C; van den Wildenberg FJH; van Berge Henegouwen MI; van Duijvendijk P; Wijnhoven BPL; Stoot JHMB; Lacle M; Ruurda JP; van Hillegersberg R;
Dis Esophagus; 2019 Dec; 32(12):. PubMed ID: 31220859
[TBL] [Abstract][Full Text] [Related]
36. Prognostic value of natural killer cell activity for patients with HER2 + advanced gastric cancer treated with first-line fluoropyrimidine-platinum doublet plus trastuzumab.
Cho H; Ryu MH; Lee HE; Kim HD; Kang YK
Cancer Immunol Immunother; 2022 Apr; 71(4):829-838. PubMed ID: 34420059
[TBL] [Abstract][Full Text] [Related]
37. Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Al-Batran SE; Homann N; Pauligk C; Illerhaus G; Martens UM; Stoehlmacher J; Schmalenberg H; Luley KB; Prasnikar N; Egger M; Probst S; Messmann H; Moehler M; Fischbach W; Hartmann JT; Mayer F; Höffkes HG; Koenigsmann M; Arnold D; Kraus TW; Grimm K; Berkhoff S; Post S; Jäger E; Bechstein W; Ronellenfitsch U; Mönig S; Hofheinz RD
JAMA Oncol; 2017 Sep; 3(9):1237-1244. PubMed ID: 28448662
[TBL] [Abstract][Full Text] [Related]
38. Liver metastases from gastric carcinoma: A Case report and review of the literature.
Polkowska-Pruszyńska B; Rawicz-Pruszyński K; Ciseł B; Sitarz R; Polkowska G; Krupski W; Polkowski WP
Curr Probl Cancer; 2017; 41(3):222-230. PubMed ID: 28625333
[TBL] [Abstract][Full Text] [Related]
39. Oligometastatic Disease (OMD): The Classification and Practical Review of Prospective Trials.
Izmailov T; Ryzhkin S; Borshchev G; Boichuk S
Cancers (Basel); 2023 Oct; 15(21):. PubMed ID: 37958408
[TBL] [Abstract][Full Text] [Related]
40. Prognostic significance of a systemic inflammatory response in patients receiving first-line palliative chemotherapy for recurred or metastatic gastric cancer.
Hwang JE; Kim HN; Kim DE; Choi HJ; Jung SH; Shim HJ; Bae WK; Hwang EC; Cho SH; Chung IJ
BMC Cancer; 2011 Nov; 11():489. PubMed ID: 22103888
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]